Analyst Ratings For NASDAQ:BMRN – BioMarin Pharmaceutical (NASDAQ:BMRN)
Today, Canaccord Genuity initiated coverage on NASDAQ:BMRN – BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy with a price target of $101.00.
Some recent analyst ratings include
- 5/16/2018-Canaccord Genuity initiated coverage with a Buy rating.
- 5/15/2018-Wedbush Reiterated Rating of Outperform.
- 3/29/2018-Credit Suisse Group Reiterated Rating of Buy.
- On 5/11/2018 Jean Jacques Bienaime, CEO, sold 18,750 with an average share price of $88.42 per share and the total transaction amounting to $1,657,875.00.
- On 5/10/2018 Brian Mueller, SVP, sold 2,450 with an average share price of $89.50 per share and the total transaction amounting to $219,275.00.
- On 5/7/2018 Jeffrey Robert Ajer, EVP, sold 309 with an average share price of $85.96 per share and the total transaction amounting to $26,561.64.
- On 4/24/2018 Jean Jacques Bienaime, CEO, sold 20,000 with an average share price of $82.43 per share and the total transaction amounting to $1,648,600.00.
- On 4/23/2018 Daniel K Spiegelman, CFO, sold 11,059 with an average share price of $82.15 per share and the total transaction amounting to $908,496.85.
- On 4/20/2018 Jean Jacques Bienaime, CEO, sold 10,000 with an average share price of $83.65 per share and the total transaction amounting to $836,500.00.
- On 4/17/2018 V Bryan Lawlis, Director, sold 3,750 with an average share price of $85.00 per share and the total transaction amounting to $318,750.00.
Recent Trading Activity for NASDAQ:BMRN – BioMarin Pharmaceutical (NASDAQ:BMRN)
Shares of NASDAQ:BMRN – BioMarin Pharmaceutical closed the previous trading session at 88.91 up +0.21 0.24% with 88.8125991821289 shares trading hands.